Literature DB >> 12083844

Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins.

Mario H Skiadopoulos1, Sonja R Surman, Jeffrey M Riggs, Claes Orvell, Peter L Collins, Brian R Murphy.   

Abstract

The level of replication and immunogenicity of recombinant parainfluenza virus type 3 (rHPIV3) bearing one, two, or three gene insertions expressing foreign protective antigens was examined. cDNA-derived recombinant HPIV3s bearing genes encoding the open reading frames (ORFs) of the hemagglutinin-neuraminidase (HN) of HPIV1, the HN of HPIV2, or the hemagglutinin (HA) of measles virus replicated efficiently in vitro, including the largest recombinant, which had three gene unit insertions and which was almost 23 kb in length, 50% longer than unmodified HPIV3. Several viruses were recovered from cDNAs whose genome length was not a multiple of six nucleotides and these contained nucleotide insertions that corrected the length to be a multiple of 6, confirming that the "rule of six" applies to HPIV3. Using a hemagglutination inhibition assay, we determined that the HPIV1 HN expressed by recombinant HPIV3 was incorporated into HPIV3 virions, whereas using this assay incorporation of the HPIV2 HN could not be detected. HPIV3 virions bearing HPIV1 HN were not neutralized by HPIV1 antiserum but were readily neutralized by antibodies to the HPIV3 HN or fusion protein (F). Viruses with inserts were restricted for replication in the respiratory tract of hamsters, and the level of restriction was a function of the total number of genes inserted, the nature of the insert, and the position of the inserted gene in the gene order. A single insert of HPIV2 HN or measles virus HA reduced the in vivo replication of rHPIV3 up to 25-fold, whereas the HPIV1 HN insert decreased replication almost 1000-fold. This indicates that the HPIV1 HN insert has an attenuating effect in addition to that of the extra gene insert itself, presumably because it is incorporated into the virus particle. Viruses containing two inserts were generally more attenuated than those with a single insert, and viruses with three inserts were over-attenuated for replication in hamsters. Inserts between the N and P genes were slightly more attenuating than those between the P and the M genes. A recombinant HPIV3 bearing both the HPIV1 and the HPIV2 HN genes (r1HN 2HN) was attenuated, immunogenic, and protected immunized hamsters from challenge with HPIV1, HPIV2, and HPIV3. Thus, it is possible to use a single HPIV vector expressing two foreign gene inserts to protect infants and young children from the severe lower respiratory tract disease caused by the three major human PIV pathogens. (c) 2002 Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12083844     DOI: 10.1006/viro.2002.1415

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  25 in total

1.  Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.

Authors:  J Brian Kimble; Delphine C Malherbe; Michelle Meyer; Bronwyn M Gunn; Marcus M Karim; Philipp A Ilinykh; Mathieu Iampietro; Khaled S Mohamed; Surendra Negi; Pavlo Gilchuk; Kai Huang; Yuri I Wolf; Werner Braun; James E Crowe; Galit Alter; Alexander Bukreyev
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

Review 2.  Nonsegmented negative-strand viruses as vaccine vectors.

Authors:  Alexander Bukreyev; Mario H Skiadopoulos; Brian R Murphy; Peter L Collins
Journal:  J Virol       Date:  2006-11       Impact factor: 5.103

3.  Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium.

Authors:  Liqun Zhang; Alexander Bukreyev; Catherine I Thompson; Brandy Watson; Mark E Peeples; Peter L Collins; Raymond J Pickles
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

4.  More antibody with less antigen: can immunogenicity of attenuated live virus vaccines be improved?

Authors:  Alexander Bukreyev; Mario H Skiadopoulos; Josephine McAuliffe; Brian R Murphy; Peter L Collins; Alexander C Schmidt
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-13       Impact factor: 11.205

Review 5.  The role of nanotechnology in the treatment of viral infections.

Authors:  Lavanya Singh; Hendrik G Kruger; Glenn E M Maguire; Thavendran Govender; Raveen Parboosing
Journal:  Ther Adv Infect Dis       Date:  2017-07-05

6.  The genome length of human parainfluenza virus type 2 follows the rule of six, and recombinant viruses recovered from non-polyhexameric-length antigenomic cDNAs contain a biased distribution of correcting mutations.

Authors:  Mario H Skiadopoulos; Leatrice Vogel; Jeffrey M Riggs; Sonja R Surman; Peter L Collins; Brian R Murphy
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

Review 7.  Ebola virus disease candidate vaccines under evaluation in clinical trials.

Authors:  Karen A Martins; Peter B Jahrling; Sina Bavari; Jens H Kuhn
Journal:  Expert Rev Vaccines       Date:  2016-05-27       Impact factor: 5.217

8.  Complete genome sequence and pathogenicity of two swine parainfluenzavirus 3 isolates from pigs in the United States.

Authors:  Dan Qiao; Bruce H Janke; Subbiah Elankumaran
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

9.  The C proteins of human parainfluenza virus type 1 (HPIV1) control the transcription of a broad array of cellular genes that would otherwise respond to HPIV1 infection.

Authors:  Jim B Boonyaratanakornkit; Emmalene J Bartlett; Emerito Amaro-Carambot; Peter L Collins; Brian R Murphy; Alexander C Schmidt
Journal:  J Virol       Date:  2008-12-03       Impact factor: 5.103

10.  Live-attenuated respiratory syncytial virus vaccines.

Authors:  Ruth A Karron; Ursula J Buchholz; Peter L Collins
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.